Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Leng Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Ward of Oncology and Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China. Hauptthemen laut MEDLINE: Autophagy, Glutathione, Drug Resistance, Neoplasm, Pancreatic Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Natural Science Foundation of China.
Abstract (Originalsprache)
KRASG12D mutation-driven pancreatic ductal adenocarcinoma (PDAC) represents a major challenge in medicine due to late diagnosis and treatment resistance. Here, we report that macroautophagy (hereafter autophagy), a cellular degradation and recycling process, contributes to acquired resistance against novel KRASG12D-targeted therapy. The KRASG12D protein inhibitor MRTX1133 induces autophagy in KRASG12D-mutated PDAC cells by blocking MTOR activity, and increased autophagic flux prevents apoptosis. Mechanistically, autophagy facilitates the generation of glutamic acid, cysteine, and glycine for glutathione synthesis. Increased glutathione levels reduce reactive oxygen species production, which impedes CYCS translocation from mitochondria to the cytosol, ultimately preventing the formation of the APAF1 apoptosome. Consequently, genetic interventions (utilizing ATG5 or BECN1 knockout) or pharmacological inhibition of autophagy (with chloroquine, bafilomycin A1, or spautin-1) enhance the anticancer activity of MRTX1133 in vitro and in various animal models (subcutaneous, patient-derived xenograft, and orthotopic). Moreover, the release of histones by apoptotic cells triggers an adaptive immune response when combining an autophagy inhibitor with MRTX1133 in immunocompetent mice. These findings establish a new strategy to overcome KRASG12D-targeted therapy resistance by inhibiting autophagy-dependent glutathione synthesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Ward of Oncology and Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China.
- DAMP Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
- Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
- Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
- Life Sciences Institute and Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, MI, 48109, USA.
- Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. Electronic address: daolin.tang@utsouthwestern.edu.
Förderung
- NIGMS NIH HHS
- National Natural Science Foundation of China
Zitieren
APA
Han, L., Meng, L., Liu, J., Xie, Y., Kang, R., Klionsky, D. J., Tang, D., Jia, Y., & Dai, E. (2024). Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217258
Vancouver
Han L, Meng L, Liu J, Xie Y, Kang R, Klionsky DJ, et al. Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217258
BibTeX
@article{Han2024,
author = {Han, Leng and Meng, Lingjun and Liu, Jiao and Xie, Yangchun and Kang, Rui and Klionsky, Daniel J and Tang, Daolin and Jia, Yuanyuan and Dai, Enyong},
title = {Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217258}
}
EUVIMED